Kelun-Biotech
科伦博泰
Executive Summary
Kelun-Biotech is the innovative arm of Kelun Pharmaceutical, a leading Chinese ADC developer based in Chengdu with proven deal execution capabilities. The company demonstrated significant BD sophistication through its landmark $9.4B+ multi-ADC licensing deal with Merck, showcasing their OptiDC linker-payload platform. With clear BIOSECURE status and strong ADC expertise, they represent a low-risk, high-value partnership opportunity for US pharma seeking oncology assets.
Structure: Kelun-Biotech operates as the innovative subsidiary of publicly-traded Kelun Pharmaceutical, likely structured to house the R&D and IP assets separate from the parent's manufacturing operations. The corporate structure appears straightforward for a Chinese biotech subsidiary, though full ownership chain verification would be needed during due diligence.
Key People
| Name | Title | Education | Flags |
|---|---|---|---|
Haiping Song 宋海平 | CEO, Kelun-Biotech | PhD, Sichuan University |
Ownership & Shareholder Structure
Kelun Pharmaceutical → Kelun-Biotech
Kelun Pharmaceutical controls Kelun-Biotech, the innovative drug discovery arm that licensed 7 ADC targets to Merck for $9.4B+.
BIOSECURE Risk
Company has clear BIOSECURE status with no BCC designation, and successful precedent of major US pharma partnership with Merck
Key Exposures:
- •Potential future policy changes affecting Chinese biotechs
- •Supply chain dependencies on Chinese CROs/CDMOs
Mitigation: Clear current status provides immediate deal flexibility, though long-term monitoring of policy developments recommended
BD Intelligence
Therapeutic Areas:
Recent Deals: Landmark $9.4B+ multi-ADC licensing deal with Merck demonstrates strong deal execution and validates platform technology
Approach: Approach with confidence given proven track record with Merck. Focus on remaining ADC pipeline assets and OptiDC platform opportunities. Haiping Song is the key decision maker.
Red Flags
- ⚠Limited public information on full pipeline beyond ADC platform
- ⚠Dependency on parent company Kelun Pharmaceutical for resources and strategic direction
- ⚠Concentration risk in ADC space
Quick Facts
- Key People
- 1
- Subsidiaries
- 0
- CDMO/CRO Subs
- 0
- Genomics Subs
- 0
- Direct BIOSECURE
- 0
- Corp Events
- 0
- Gov-Connected
- 0
- Clinical Trials
- 0
- Publications
- 0
- Drug Molecules
- 0
- Relationships
- 2
Sources & Methodology
Clinical trials data: ClinicalTrials.gov API v2 (0 trials linked to this entity)
SEC BIOSECURE filings: EDGAR EFTS full-text search (850+ filings from 230 companies)
Publications: Europe PMC API (0 publications indexed)
Drug molecules: ChEMBL database (European Bioinformatics Institute)
Financial data: East Money (东方财富) datacenter API / CNINFO (巨潮资讯网)
Corporate structure: Company official filings, HKEX/SSE/SZSE disclosures
Executive profiles: Company official biographies, SEC filings, LinkedIn (where verified)
Data is collected from public sources and updated weekly. Corporate intelligence is verified by a native Mandarin-speaking analyst against Chinese-language primary sources including Tianyancha (天眼查), GSXT (国家企业信用信息公示系统), and CNINFO (巨潮资讯网). This is not financial or legal advice.